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Abstract
The WTH3 gene was obtained by a DNA fragment isolated by the methylation-sensitive representational difference
analysis technique due to its hypermethylation in the human multidrug resistant (MDR) breast cancer cell line MCF7/
AdrR. The WTH3 gene product is 89% and 91% identical to the human Rab6 and Rab6c proteins, but possesses an
elongated C-terminal region which contains 46 extra amino acids. Nevertheless, we consider the WTH3 gene a new member
of the Rab6 gene family. Semi-quantitative reverse transcriptase^polymerase chain reaction results showed that WTH3 was
15 and 4 times downregulated in MCF7/AdrR and MES-SA/Dx5, a human MDR uterine sarcoma cell line, as compared to
their non-MDR parental cell lines. Permanent expression of the WTH3 transgene in MDR cell lines increased to varying
degrees their sensitivity to several anticancer drugs, which included doxorubicin, taxol, vinblastine, vincristine, and
etoposide, as compared to the control sublines transfected with the empty vector. Flow cytometry and fluorescence
microscope experiments suggest that the WTH3 transgene stimulated the host’s uptake and retention of DOX. Our results
imply that the WTH3 gene plays a role(s) in MDR phenotype development in vitro. ? 2002 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Although MDR1 and MRP genes [1^6], as well as
other gene products, such as lung resistance-related
protein (LRP) and glutathione transferase [7^9], have
been widely recognized as factors involved in MDR
development, the clinical MDR phenomenon is still
not completely understood. Clearly other unknown
drug resistant mechanisms are at work [10,11].
Therefore searching for those mechanisms, with the
help of modern techniques, may provide information
of great importance in understanding the etiology of
clinical MDR.
One strategy, which could be utilized to uncover
these hidden systems, is the study of DNA methyla-
tion. This event suppresses gene expression which
may cause distinct cellular phenotypes [12^14]. For
example, a correlation between DNA methylation,
gene expression, and drug resistance has been re-
ported by several scienti¢c groups [15^19]. In addi-
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tion, a methylated site is usually found close to the
5P end of the gene to be regulated [20^22], and
therefore a di¡erentially methylated DNA fragment
could be a useful tool in the search for genes related
to MDR. Considering this we employed methyla-
tion-sensitive representational di¡erence analysis
(MS-RDA) [23,24], which is an RDA [25] based
technology, to search for DNA fragments which
were hypermethylated in a MDR human breast can-
cer cell line, MCF7/AdrR, but not in its non-MDR
parental cell line, MCF7/WT. Both cell lines were
gifts from Dr. K. Cowan of the National Cancer
Institute [26].
As a result, a hypermethylated DNA fragment,
W3, was isolated by MS-RDA. The study of W3
has led to the discovery of two genes, Rab6c [27]
and WTH3. In this report we present our ¢ndings
related to WTH3, which was acquired by performing
the 3P-RACE (rapid ampli¢cation of cDNA ends)
technique based on the W3 sequence. WTH3 is ho-
mologous to the human Rab6 and Rab6c/Rab6AP
genes [27^29] but possesses its own unique feature,
an extended 46-amino-acid C-terminal region (re-
cently, this gene has been documented by another
group [30]). Consistent with its hypermethylated sta-
tus, the WTH3 gene was 15 times less expressed in
MCF7/AdrR than in MCF7/WT cells. In addition, it
was four times less expressed in the MES-SA/Dx5
cell line (its MDR phenotype was induced from the
parental cell line, MES-SA, by doxorubicin (DOX)
(ATCC Inc.) [31,32]) as compared to MES-SA. Re-
search on the stable MCF7/AdrR and MES-SA/Dx5
cell lines which contained the WTH3 transgene sug-
gest that WTH3 reversed the host cells’ MDR phe-
notype to several anticancer drugs tested and in-
creased DOX retention of the host cells. Our
studies indicate that the WTH3 gene, functioning
as a negative regulator, was involved in the evolution
of drug resistance in the working model systems.
Whether WTH3 is also involved in clinical drug re-
sistance is currently under investigation.
2. Experimental procedures
2.1. Human cell lines and culture conditions
MCF7/AdrR, MCF7/WT, MES-SA/Dx5, and
MES-SA cells were grown under the conditions as
described [27].
2.2. MS-RDA
To study hypermethylation events in MCF7/AdrR
cells, MCF7/WT DNA was used as tester, while
MCF7/AdrR DNA was used as driver. MS-RDA
was performed as described [23].
2.3. Amplicon and genomic methylation sensitive
Southern analysis
Amplicon Southern blot was performed as de-
scribed [23]. Two hundred and ¢fty ng of tester
and driver amplicon DNA were utilized. Genomic
methylation sensitive Southern blot was performed
as described [23].
2.4. DNA Sequencing
Polymerase chain reaction (PCR) products were
sequenced using a Dye-Labeled Sequence kit (Perkin
Elmer) under conditions speci¢ed by the manufac-
turer.
2.5. Obtaining the WTH3 Gene by 3P-RACE
A unique sequence, 5P-GATGGAACAATCGGG-
CTTCG-3P (PW3-1), which is located in the middle
of the W3 fragment, was designed as a PCR primer
to obtain the 3P end portion of the WTH3 gene from
a combined human cDNA library (Quick-Screen Hu-
man cDNA library Panel, Clontech). The antisense
primer (PV-1), 5P-ACGACTCACTATAGGGCGA-
ATTGGC-3P, was designed based on the vector se-
quence. PCR ampli¢cation was performed using the
Advantage GC KlenTaqPolymerase Mix kit (Clon-
tech) following the manufacturer’s instructions. A 1.3
kb PCR product was generated and sequenced.
Based on the sequencing information, another W3-
speci¢c primer, 5P-AAACAGTCAGCGAAGGGG-
GT-3P (PW3-RACE1), which is close to the stop
codon, was designed to perform RACE to obtain
another PCR product to verify that the original
PCR product is our true target. To acquire an intact
gene, PW3-1 was paired with another primer, 5P-C-
CCAAGCTTGACTTTTTTTGTGCTTGTCAAGC-
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Fig. 1. (A) Agarose gel electrophoresis of amplicon and di¡er-
ence products generated by MS-RDA from MCF7/WT DNA.
Lane M represents HaeIII P174 markers. Lane a represents the
tester amplicon. Lanes b and c contain the di¡erence products
after ¢rst and second round subtraction hybridization/PCR am-
pli¢cation. (B) Results of the amplicon and genomic Southern
blot for hypermethylated W3. The arrows indicate the frag-
ments that are hybridized with the radiation labeled W3 and
control probes. In lanes D and T, each probe hybridizes with
250 ng of driver (MCF7/AdrR) and tester (MCF7/WT) ampli-
con DNA. In lanes R1 and W1, the W3 probe hybridized with
6 Wg of HpaII-digested genomic DNA isolated from MCF7/
AdrR and MCF7/WT cells, respectively. In Lanes R2 and W2,
each probe hybridized with 6 Wg of MspI-digested genomic
DNA also isolated from MCF7/AdrR and MCF7/WT. The
completion of enzymatic digestion for all genomic DNAs was
con¢rmed by a control probe which was a background DNA
fragment isolated by MS-RDA.
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3P (PW3-RACE2), which is located beyond the stop
codon and followed by an arti¢cial HindIII restric-
tion enzyme site (for cloning purposes), to generate
the 3P end of the gene. This PCR product was di-
gested by BglII, an endogenous site, and HindIII. To
obtain the intact WTH3 gene, the BglII/HindIII frag-
ment was then subcloned into the pUC118-W3 plas-
mid containing the W3 sequence, which was also
digested by BglII, the corresponding endogenous
site, and HindIII, which is in the polylinker, to re-
lease the truncated 3P end region.
2.6. Semi-quantitative reverse
transcriptase^polymerase chain reaction
(SQRT^PCR) and RT^PCR
Total RNAs were isolated from the cell lines by
the RNA isolation kit, RNA STAT-60 (TEL-TEST).
The ¢rst-strand cDNA was synthesized by Super-
Script Preampli¢cation System Kit (Life Technolo-
gies). SQRT^PCR was performed by utilizing PW3-
1, the WTH3 gene sense primer, and the antisense
primer, 5P-GCTGCTACACGTCGAAAGAGC-3P,
while the cDNAs of MCF7/AdrR, MCF7/WT,
MES-SA/Dx5, and MES-SA served as templates.
The length of the WTH3 PCR product was 341 bp.
The sense and antisense primers for G3PDH (internal
control) were 5P-CGGAGTCAACGGATTTGGT-
CGTAT-3P and 5P-AGCCTTCTCCATGGTGGT-
GAAGAC-3P. The length of the G3PDH PCR prod-
uct was 284 bp. To con¢rm exogenous WTH3 gene
expression in the stable cell line, PW3-RACE1 was
employed as the sense primer. A sequence in the
polylinker of the pcDNA3.1 (Invitrogen) vector, 5P-
CACTGTGCTGGATATCTGCAG-3P (PV-2), was
Fig. 3. Results of WTH3-speci¢c SQRT^PCR. M represents
HaeIII P174 markers. The cell lines used to prepare cDNA for
simultaneously generated WTH3 and G3PDH PCR products
are indicated by numbers: 1, MES-SA/Dx5; 2, MES-SA; 3,
MCF7/AdrR; 4, MCF7/WT. Lanes 5 and 6 contain WTH3 and
G3PDH PCR products generated from cDNA prepared from
MCF7/WT cells, which served as positive controls. Lane 7 is
the PCR negative control.
Table 1
E¡ects of drugs on WTH3 transfected MES-SA/Dx5 clone cells
Drugs ME-V ME-2 ME-4 ME-7
IC50 (nM) N SF IC50 (nM) N SF IC50 (nM) N SF IC50 (nM) N SF
(range, nM) (range, nM) (range,
nM)
(range, nM)
DOX 770 22 93.3 54
(700^900) 5 1 (9^26) 5 35 (85^130) 5 8.3 (45^100) 5 14.3
TAX 615 2.85 28 20.5
(490^700) 4 1 (1.92^3.0) 4 216 (16^30) 3 22 (9^25) 3 30
VBL 59 1.3 7 3.6
(45^70) 4 1 (0.3^1.5) 7 45 (5^13) 4 8.4 (2.8^5.8) 4 16.4
VCR 408 2.35 30.7 14.5
(380^480) 5 1 (0.2^3.2) 11 174 (28^60) 5 13 (6^35) 5 28
VP-16 8900 340 2300 1050
(6900^11000) 4 1 (320^500) 4 26 (500^2700) 4 4 (600^1900) 4 8.5
CISP 1400 810 1413 1180
(1200^1500) 4 1 (640^840) 4 1.7 (1325^1775) 4 1 (420^1400) 4 1.2
Fig. 2. The comparison of nucleotide sequences between
WTH3, Rab6, and Rab6c (A) and the comparison of amino
acid sequences between WTH3, Rab6, and Rab6c (B). The W3
fragment isolated by MS-RDA is in italics. The nucleotide and
amino acid substitutions between the three genes are in bold
type. The di¡erences between WTH3 and Rab6 and their prod-
ucts are marked with dots, while the di¡erences between WTH3
and Rab6c and their products are marked with stars. The start
and stop codons of the genes are underlined.
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Fig. 4. Growth inhibition of ME-2 cells caused by di¡erent concentrations of DOX, CISP, TAX, VBL, VCR, and VP-16 (A) and
QRT^PCR of the expressed exogenous WTH3 gene in ME-2, ME-4, and ME-7 cells (B). (A) The line formed by linking the solid
circles or squares represents the survival rate of ME-V and ME-2 cells (mean of more than four experiments), respectively. The thin
bars represent standard deviation. (B) Lane M represents HaeIII P174 markers. Lanes 5 and 6 contain the positive controls for
WTH3 and L-actin. The product in lane 5 was generated by using cDNA prepared from ME-2 RNA and WTH3-speci¢c primers. The
product in lane 6 was generated from cDNA prepared from MES-SA/Dx5 cells. Lanes 1, 2, and 3 contain simultaneously generated
WTH3 and L-actin PCR products by utilizing cDNAs which were prepared from ME-2, ME-4, and ME-7 cells. Lane 4 only contains
L-actin generated from cDNA prepared from ME-V cells, although L-actin- and WTH3-speci¢c primers were simultaneously added.
Lane 7 is the negative control.
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used as antisense primer to synthesize the WTH3
transgene fragment (226 bp). The sense and antisense
primers for generating the L-actin fragment (495 bp)
which served as a control were 5P-GACGACATG-
GAAGATCTGG-3P and 5P-ATCGGGCAGCTCG-
TAGCTCTTCC-3P. The PCR and quanti¢cation of
PCR products were performed as described [27].
2.7. Generation of stable cell lines
The PCR-generated WTH3 gene was subcloned
into the mammalian expression vector, pcDNA3.1,
to create pcDNA3.1/WTH3. The gene sequence was
con¢rmed by DNA sequencing. MCF7/AdrR and
MES-SA/Dx5 cells grown to 60% con£uence in 60-
mm dishes were transfected with 2 Wg of pcDNA3.1/
WTH3, or pcDNA3.1 (control) plasmid using a cal-
cium phosphate precipitation kit (5 Prime 3 Prime).
The transfected MCF7/AdrR and MES-SA/Dx5 cells
were maintained in medium supplied with 200 and
250 Wg/ml of neomycin analogue G418 (Gibco), re-
spectively. Stable G418 resistant populations were
acquired after 2 weeks of selection. The individual
clones were obtained by limiting dilution.
2.8. Cell growth inhibition
Approximately 1U103/well of WTH3 or the empty
vector transfectants were seeded in a 96-well plate
(Corning Costar) and grown overnight. DOX, cispla-
tin (CISP), taxol (TAX), vinblastine (VBL), vincris-
tine (VCR), and etoposide (VP-16) (Sigma) were se-
Fig. 5. Analysis of DOX uptake in ME-V and ME-2 cells by
£ow cytometry. DOX uptake in each cell group is presented by
a peaked graph (A), and DOX uptake and retention in each
group is presented by a curved graph (B). (A) Comparison of
intercellular £uorescence in ME-V versus ME-2 cells. a, ME-V,
at 0 (dashed line) and 2 h incubation with DOX (thin solid
line) ; b, ME-2, at 0 (dashed line) and 2 h incubation with
DOX (thick solid line) ; c, the comparison of accumulated
DOX £uorescence in ME-V (thin solid line) and ME-2 (thick
solid line) at 2 h incubation. (B) Cells were treated with DOX
for 2 h and then washed. The cells remained in a DOX-free
medium for up to 4 h. The intercellular £uorescence at di¡erent
time points was measured by a £ow cytometer. The solid and
dashed lines represent ME-V and ME-2 cells, respectively. The
solid points are the means of duplicated determinations. The
vertical bars represent the upper or lower range at that data
point.
6
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rially diluted into ten concentrations. Every group of
four wells received one drug concentration. After a
6-day incubation period, the cells were treated with
3-[4,5-dimethylthiazol-Z-yl]-2-5-diphenyl-tetrazolium
bromide (MTT) which stains living cells. IC50 was
quantitatively evaluated as described [27].
2.9. Flow cytometry
Approximately 5U105/well of WTH3 or the empty
vector transfected cells were seeded in six-well dishes.
Since the intracellular £uorescence intensity was
tested at seven time points, seven wells for each
transfectant group were prepared. One well for
each group was not treated by DOX and served as
the 0 time control. Each group of six wells was in-
cubated with 30 Wg/ml DOX in 1 ml of culture media
for 2 h at 37‡C in 5% CO2. To measure the intra-
cellular £uorescence intensity, the cells were washed
twice in ice cold PBS and trypsinized. Cells were
centrifuged at 1000 rpm for 5 min to pellet and
then resuspended in 300 Wl of 1% paraformaldehyde.
Fig. 6. Fluorescence microscopy of DOX accumulation and distribution assay. ME-V (A,B) and ME-2 (C,D) cells were loaded with
DOX for 2 h (A,C, bright ¢eld; B,D, £uorescent ¢eld). Experiments were performed three times giving similar results. U150.
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The intracellular DOX £uorescence content was
analyzed by £ow cytometry as described [33]. The
£uorescence intensity was measured at 1- and 2-h
intervals during the DOX incubation period. The
remaining four wells of each transfectant were then
washed twice with ice-cold PBS and incubated in a
DOX-free culture medium for 4 h. The intensity of
£uorescence at 1, 2, 3, and 4 h of chase was mea-
sured.
2.10. Fluorescence microscopic assay
Approximately 5U104/well of WTH3 or the empty
vector transfectants were cultured in six-well dishes.
Individual wells were incubated with 10 Wg/ml DOX
in medium for 2 h. Medium was then removed and
the cells were washed with ice-cold PBS, followed by
the addition of fresh media without DOX. Cells were
immediately examined for £uorescence at 488 nm
excitation wavelength by £uorescence microscopy.
The GenBank accession number for WTH3 is
AF309646 (it will be released when the gene is pub-
lished), and that for W3 is AF11936.
3. Results
3.1. Isolation of a hypermethylated DNA fragments
by MS-RDA
After two rounds of DNA subtractive hybridiza-
tion and PCR ampli¢cation, individual fragments,
considered di¡erence products, were isolated from
the MCF7/WT cells (Fig. 1A). These fragments
were then subcloned into the pUC118 vector, and
the candidate inserts were screened by amplicon
Southern analysis. One of the candidate probes was
W3, since it only hybridized with the tester, but not
driver amplicon DNA (Fig. 1B). To prove that W3
was hypermethylated in MCF7/AdrR cells, it was
used as the probe to perform methylation sensitive
Southern blot. Both cell lines’ genomic DNAs were
digested by HpaII or the MspI enzyme. MspI is an
isoschizomer of HpaII, but not sensitive to CmCGG.
Therefore, MspI could cleave a methylated site which
could not be cut by HpaII. Southern analysis results
indicated that W3 was hypermethylated in the
MCF7/AdrR DNA because MspI digestion released
a band which was not cleaved by the HpaII enzyme
(Fig. 1B).
The W3 fragment was sequenced and found to
contain 573 bp which shared 89% and 96% identity
with the corresponding portion of the human Rab6
and Rab6c/Rab6AP genes [27^29]. Based on protein
sequence analysis, W3 encodes 175 amino acids with-
out an interruption. In addition, at its 5P end there is
a stop codon, TAG, that is 27 bp away from a start
codon. This suggested that the complete N terminus
of the putative gene was included in the W3 frag-
ment, however, the C-terminal region was missing
(Fig. 2A,B).
3.2. Obtaining the WTH3 gene by 3P-RACE
To acquire the putative full length cDNA of W3,
the RACE technique was employed where a com-
bined cDNA panel of di¡erent cell types (a commer-
cial product of Clontech) was used as a template. To
obtain the missing 3P end portion of the candidate
gene, a primer, PW3-1, paired with an antisense
primer, PV-1, which was the vector’s sequence close
to the junction of the cDNA insertion, were utilized
to perform PCR ampli¢cation. PW3-1 is a speci¢c
primer for W3, since in its 20 bp length sequence
there are eight and three substitutions as compared
to the corresponding region in Rab6 and Rab6c. This
speci¢c feature was con¢rmed by the fact that no
PCR product was generated from the plasmid con-
taining Rab6 or Rab6c sequences when PW3-1 and
an antisense primer, a common sequence in Rab6,
Rab6c, and W3, were used (data not shown). As a
result of PCR ampli¢cation, a single 1.3 kb length
PCR fragment was generated. This fragment was
then electrophoresis-puri¢ed and sequenced. Our
¢ndings suggested that the PCR product was our
target since the initial 349 bp sequence matched per-
fectly to the corresponding region of the W3 se-
quence. Furthermore, in the middle of the PCR
product, there was a stop codon which ended a
220-amino-acid stretch. To verify these results, an-
other primer, PW3-RACE1, which is beyond W3’s
3P region and before the stop codon, was used to
perform a second RACE. PW3-RACE1 contains
4 bp substitutions as compared to the corresponding
regions in Rab6 and Rab6c, and is speci¢c for the
extended W3 sequence. A PCR product approxi-
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mately 800 bp in length was ampli¢ed. Sequence
analysis con¢rmed that the N-terminal was identical
to the corresponding sequence of the ¢rst PCR
product. To further prove the accuracy of the
PCR products, we generated the missing 3P end por-
tion of the target gene, W3-3P, from two other
human cDNA libraries (Kidney and Brain cDNA
libraries, Clontech). This was accomplished by utiliz-
ing the PW3-1 primer paired with the PW3-RACE2
primer which was located beyond the stop codon.
Sequence analysis con¢rmed that both PCR products
were identical to the two sequences previously gen-
erated by RACE. Therefore, we were convinced that
the entire sequence information for the target gene
had been obtained. We named this gene WTH3 due
to the fact that its truncated portion was originally
isolated from MCF7/WT by Hpa II cleavage MS-
RDA.
To acquire an intact WTH3 gene, the W3-3P frag-
ment was digested with BglII and HindIII. The BglII
site is an endogenous sequence, while the HindIII site
was added into the PW3-RACE2 primer for cloning
purposes. At the same time, the pUC118-W3 con-
struction, which contains the W3 DNA fragment iso-
lated by MS-RDA, was also digested with BglII and
HindIII to release the truncated region and create
pUC118-W33. The enzymatic treated W3-3P was
then ligated to the linearized pUC118-W33 to obtain
the full-length WTH3 gene. Di¡ering from Rab6 and
Rab6c, which both encode a 208-amino-acid product,
the WTH3 cDNA encodes a 254-amino-acid protein.
In the corresponding 718 bp sequences, WTH3 is
92% and 95% identical to Rab6 and Rab6c (Fig.
2A), while in the corresponding 208-amino-acid se-
quences, WTH3 is 89% and 91% identical to Rab6
and Rab6c (Fig. 2B). In addition, compared to the
Rab6 and Rab6c genes, WTH3 has an elongated C-
terminal region consisting of 46 amino acids (Fig.
2B). Recently, the Wiemann group reported that
they have obtained 500 new cDNAs, among these,
a Rab6-like gene was 100% identical to WTH3 [30].
This ¢nding veri¢es the sequence accuracy of the
WTH3 gene.
3.3. The WTH3 gene was underexpressed in
MCF7/AdrR and MES-SA/Dx5 cells
Since the N-terminal portion of the WTH3 gene,
W3, was hypermethylated in MCF7/AdrR cells, the
WTH3 gene’s expression level in MCF7/AdrR and
MCF7/WT cells was analyzed by SQRT^PCR using
gene-speci¢c primers. The predicted size of the
WTH3 PCR product was 341 bp, while 284 bp
was the anticipated length of the G3PDH gene
which served as a quantitative control. The results
showed that the expression of WTH3 in MCF7/
AdrR cells was 15 times less than that in MCF7/
WT cells (Fig. 3). In addition, the WTH3 gene’s
expression level was evaluated in the MDR cell
line MES-SA/Dx5 and its non-MDR counterpart
MES-SA. We found that WTH3 was four times
less expressed in MES-SA/Dx5 as compared to
MES-SA cells (Fig. 3).
3.4. Drug-induced WTH3 transfectants growth
inhibition assays
Hypermethylation and low expression of the
WTH3 gene in MCF7/AdrR and MES-SA/Dx5 cells
indicated that this gene might be a negative regulator
for drug resistance. To test this hypothesis and ob-
tain reliable results, both MCF7/AdrR and MES-SA/
Dx5 were transfected with the WTH3 gene to gen-
erate stable cell lines. Another reason for using the
MES-SA/Dx5 line was that it exhibited a much
weaker MDR phenotype than MCF7/AdrR. There-
fore, the WTH3 gene could have a stronger in£uence
on MES-SA/Dx5 than MCF7/AdrR cells.
The WTH3 gene was generated by PCR and sub-
cloned into the pcDNA3.1 vector to create
pcDNA3.1/WTH3. This construction and the vector
were separately introduced into the host cells by cal-
cium phosphate precipitation procedure. The trans-
fected cells were maintained in medium containing
G418 for selecting stable transformed populations.
After verifying, by measuring their IC50s, that the
stable populations harboring the transgene exhibited
higher sensitivity to DOX than the controls inte-
grated with the empty vector, limiting dilution was
carried out to obtain stable cell clones. Three MCF7/
AdrR and ¢ve MES-SA/Dx5 individual transfectants
were selected. Limiting dilution procedures were also
carried out to obtain ¢ve individual MCF7/AdrR or
MES-SA/Dx5 transfectants integrated with the
empty vectors (negative controls). The expression of
the exogenous WTH3 gene in each clone was con-
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¢rmed by RT^PCR, where the gene-speci¢c primer
PW3-1 and pcDNA3.1 poly-linker primer PV-2 were
used. All clones, along with their controls, were uti-
lized for drug-induced cell growth inhibition assays.
IC50s for the anticancer drugs DOX, CISP, TAX,
VBL, VCR, and VP-16 were evaluated. We found
that the transgene increased the MCF7/AdrR clones’
sensitivity to DOX, TAX, VBL, and VCR by factors
ranging from 2- to 6-fold (data not shown). How-
ever, the transgene had a much stronger in£uence on
four out of ¢ve MES-SA/Dx5 clones. For example,
both clones #2 (ME-2) and #8 (ME-8) had signi¢-
cant increased sensitivity to DOX, TAX, VBL, VCR,
and VP-16 as compared to the ¢ve controls contain-
ing the empty vector (ME-V). The sensitivity of
clones #4 (ME-4) and #7 (ME-7) to the same drugs
was also elevated by the transgene but to a lesser
extent. Clone #5, which expressed a very low level
of the transgene, exhibited a drug resistant pheno-
type similar to that of all ¢ve control sublines (data
not shown). In the next paragraph, detailed informa-
tion on the IC50 measurements of clones ME-2, ME-
4, and ME-7 is presented.
To determine the IC50s, ME-2, ME-4, ME-7, and
¢ve ME-V sublines were kept in media without the
drug, or with the other ten drug concentrations for 6
days. More than three individual experiments were
performed for each cloned cell line. The IC50 mea-
surements found that the WTH3 transgene in-
creased the host clone’s sensitivity to DOX, TAX,
VBL, VCR, and VP-16, but not to CISP, to varying
degrees as compared to the control cell lines which
exhibited the original MDR phenotype (Table 1).
Since all ¢ve ME-V controls had similar resistance
to the drugs tested, only the results obtained from
one ME-V were listed. The sensitivity of the ME-2
clone to DOX, TAX, VBL, VCR, and VP-16 was 35,
216, 45, 174, and 26 times greater than that of the
control cells (Table 1 and Fig. 4A). The ME-4
clone’s sensitivity to the same anticancer drugs was
8, 22, 8, 13, and 4 times higher than the control
cells, while that of the ME-7 clone was elevated
14, 30, 16, 28, and 8.5 times relative to the control
(Table 1). Expression of the WTH3 transgene in
ME-2, ME-4, and ME-7 was veri¢ed by RT^PCR
(Fig. 4B). Densitometer analysis found that the ex-
pression level of the transgene in ME-2 was 1.6 and
2.2 times higher than that in ME-7 and ME-4,
which could be a reason for ME-2 exhibiting higher
drug sensitivity.
3.5. Flow cytometry assay for DOX uptake and
retention in ME-2 cells
DOX is £uorescent, and this attribute provides
easy monitoring of its intracellular accumulation by
£ow cytometry. Thus, ME-V and ME-2 cells were
incubated with DOX for 2 h, after which the cells
were washed and remained in a medium without
DOX for 4 h. DOX uptake and retention in the cells
was quantitatively determined at di¡erent time points
(see Section 2). The ME-V cells displayed no signi¢-
cant increase in cellular £uorescence after DOX in-
cubation. The ME-2 cells, which contained the
WTH3 transgene, however, displayed greatly in-
creased DOX uptake (Fig. 5A). Furthermore, the
intensity of £uorescence in ME-2 and ME-V cells
was measured at four time points after the cells
were washed with PBS bu¡er. The results showed
that the £uorescence remained much stronger even
after 4 h of chase in ME-2 than that in ME-V cells
(Fig. 5B). These ¢ndings clearly demonstrate the pos-
itive e¡ect of the WTH3 gene on DOX uptake and
retention in the host cells.
3.6. Fluorescence microscopy of DOX accumulation in
ME-2 cells
Flow cytometry experiments found that the WTH3
gene stimulated the host cells’ uptake and retention
of DOX. To visually determine the intercellular lo-
cation of the accumulated DOX, £uorescence mi-
croscopy was performed. The ME-V and ME-2 cells
were treated with DOX for 2 h, after which the drug
was washed away. The £uorescence accumulation
and distribution in the control and test cells were
examined under a microscope (Fig. 6A^D). It was
discovered that the control cells with the drug resis-
tant phenotype only contained trace amounts of £uo-
rescence (Fig. 6B), while strong £uorescence was dis-
played in the nucleus and cytoplasm of the ME-2
cells (Fig. 6D). The intensity of £uorescence contin-
ued to remain strong even after 3 h of chase in the
ME-2 cells (data not shown).
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4. Discussion
The WTH3 gene was discovered due to hyper-
methylation of its N-terminal portion in MCF7/
AdrR cells. Function analysis suggests that this
gene could be involved in cellular MDR phenotype
development.
WTH3 is homologous to the human genes, Rab6
and Rab6c. Rab6 is thought to control intra-Golgi
transport by acting as an inhibitor [34]. Our previous
studies suggest that Rab6c is involved in developing
the MDR phenotype in MCF7/AdrR cells [27].
Rab6c was also named Rab6AP in a recent publica-
tion where it has been suggested that it is an isoform
of Rab6 due to alternative splicing. However, Ra-
b6AP is not able to stimulate Golgi-to-endoplasmic
reticulum retrograde transport as described previ-
ously for Rab6 [29]. Both Rab6 and Rab6c encode
208 amino acids with only three substitutions be-
tween them. WTH3 encodes 254 amino acids with
22 and 19 substitutions as compared to Rab6 and
Rab6c. These substitutions are evenly distributed,
and this would indicate that WTH3 is not an alter-
native spliced product of Rab6. Four domains of the
K-ras protein involved in GTP/GDP binding are also
included in WTH3 (corresponding to residues 20^27,
67^73, 123^130, and 153^159) [28]. This implies that
WTH3 encodes a small G protein. However, di¡er-
ing from Rab6 and Rab6c, WTH3 does not possess
any cysteine near its COOH terminus. The existence
of cysteine is assumed to be necessary for many G
proteins’ fatty acylation, membrane association, and
biological function [35]. The C-terminal diversi¢ca-
tion suggests that the WTH3 protein might have its
own unique utilities, even though WTH3 and Rab6c
do share some biological functions.
Our studies demonstrated that the N-terminal por-
tion of WTH3 was hypermethylated in MCF7/AdrR
and the gene was less expressed in MCF7/AdrR and
MES-SA/Dx5 cells than in their parental cell lines. In
addition, based on information provided by the Wie-
mann group, the 398 bp length region located at the
N-terminus of WTH3 was not only GC-rich (V71%
of GC content) but also contained CpG islands [30].
Although the promoter of WTH3 has not yet be-
come available, its expression could be regulated by
DNA methylation. This is because hypermethylation
in promoters is often accompanied by hypermethyla-
tion in the 5P transcribed region, and CpG islands
usually extend from promoters into the 5P tran-
scribed region [20,36^38]. It is expected that when
the promoter of WTH3 is found, a reverse correla-
tion between DNA methylation and gene expression
will be ascertained.
To test whether increasing the WTH3 gene tran-
script in MCF7/AdrR and MES-SA/Dx5 cells could
convert the MDR phenotype, stable cloned cell lines
were established. Several clones from each cell line
were generated and used to perform drug-induced
cell death experiments. The results demonstrated
that the gene in£uenced both MDR cell lines
although the e¡ect is greater on MES-SA/Dx5 than
MCF-7/AdrR. The mechanism for this disparity re-
mains unclear. In the past, we reported that the
Rab6c gene was involved in MDR in MCF7/AdrR
cells. To date, our results suggest that another Rab6-
like gene, WTH3, was also related to the MDR phe-
notype in two human cell lines. Di¡ering from
known MDR genes, which function as positive reg-
ulators for MDR development, the Rab6 genes play
negative regulation roles. It will be interesting to
understand the biological pathway(s) of each mem-
ber in the Rab6 gene family and explore the possible
relationships between them and P-glycoprotein. It
has been reported that the mammalian Rab6 gene
product was located in the medial and trans Golgi
cisternae as well as the trans Golgi network
[29,34,39], while P-glycoprotein was localized in the
plasma membrane of drug-resistant cells. However,
whether there is direct or indirect interaction between
Rab6 and P-glycoprotein remains unclear.
The question of whether the WTH3 protein di-
rectly interacts with P-glycoprotein also remains to
be determined. This is because, di¡ering from Rab6,
WTH3 does not possess any cysteine near its carbox-
yl-terminal region, suggesting it might have a di¡er-
ent cellular localization. The cellular location of
WTH3 could conceivably be determined by tagging
it with certain markers, such as green £uorescence
protein (GFP), or, most ideally, by an antibody
which could only recognize WTH3, but not Rab6
and Rab6c. When such an antibody is available, it
will assist the study of determining the possible rela-
tionship between WTH3 and P-glycoprotein.
Based on our data, it is necessary to further inves-
tigate the Rab6 genes’ (Rab6, Rab6c, and WTH3)
BBAMCR 14842 3-5-02 Cyaan Magenta Geel Zwart
J. Shan et al. / Biochimica et Biophysica Acta 1589 (2002) 112^123122
involvement in MDR evolution. The results of this
study could have a great impact in understanding
clinical MDR development.
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